Cargando…

Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis

BACKGROUND: Allergen immunotherapy (AIT) is effective in patient with local allergic rhinitis (LAR). However, AIT may not always achieve the optimal treatment effect. OBJECTIVE: To present short study with clinical cases of LAR combined therapy with sublingual immunotherapy (SLIT) and omalizumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozek, Andrzej, Kozłowska, Renata, Misiołek, Maciej, Ścierski, Wojciech, Gawlik, Radosław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746402/
https://www.ncbi.nlm.nih.gov/pubmed/35816437
http://dx.doi.org/10.1080/21645515.2022.2097818
_version_ 1784849350645514240
author Bozek, Andrzej
Kozłowska, Renata
Misiołek, Maciej
Ścierski, Wojciech
Gawlik, Radosław
author_facet Bozek, Andrzej
Kozłowska, Renata
Misiołek, Maciej
Ścierski, Wojciech
Gawlik, Radosław
author_sort Bozek, Andrzej
collection PubMed
description BACKGROUND: Allergen immunotherapy (AIT) is effective in patient with local allergic rhinitis (LAR). However, AIT may not always achieve the optimal treatment effect. OBJECTIVE: To present short study with clinical cases of LAR combined therapy with sublingual immunotherapy (SLIT) and omalizumab in patients with house dust mite (HDM) allergy and compared it to therapy with omalizumab alone. METHODS: Patients with severe LAR and hypersensitivity to HDMs were included. SLIT for HDMs was launched in a perennial protocol using SQ-HDM SLIT tablets with omalizumab. The total rhinitis symptom score (TRSS), total medication score (TMS) and combined total score (CTS) were assessed after one year. RESULTS: After 12 months, significant improvements in all analyzed parameters in the patients on SLIT+ omalizumab therapy were observed: a reduction in the TRSS from 1.21 ± 0.33 to 0.6 ± 0.28 (p < .05), a reduction in the TMS from 2.25 ± 1.05 to 0.88 ± 0.31 (p < .05) and a reduction in the CTS from 3.46 ± 0.57 to 1.48 ± 0.51 (p < .05). This improvement in TRSS, TMS also in CTS was significantly greater than in the rest of the group with SLIT alone or omalizumab alone. CONCLUSION: Omalizumab may be a valuable treatment that increases the effectiveness of immunotherapy in patients with severe LAR.
format Online
Article
Text
id pubmed-9746402
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97464022022-12-14 Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis Bozek, Andrzej Kozłowska, Renata Misiołek, Maciej Ścierski, Wojciech Gawlik, Radosław Hum Vaccin Immunother Immunotherapeutics – Short Report BACKGROUND: Allergen immunotherapy (AIT) is effective in patient with local allergic rhinitis (LAR). However, AIT may not always achieve the optimal treatment effect. OBJECTIVE: To present short study with clinical cases of LAR combined therapy with sublingual immunotherapy (SLIT) and omalizumab in patients with house dust mite (HDM) allergy and compared it to therapy with omalizumab alone. METHODS: Patients with severe LAR and hypersensitivity to HDMs were included. SLIT for HDMs was launched in a perennial protocol using SQ-HDM SLIT tablets with omalizumab. The total rhinitis symptom score (TRSS), total medication score (TMS) and combined total score (CTS) were assessed after one year. RESULTS: After 12 months, significant improvements in all analyzed parameters in the patients on SLIT+ omalizumab therapy were observed: a reduction in the TRSS from 1.21 ± 0.33 to 0.6 ± 0.28 (p < .05), a reduction in the TMS from 2.25 ± 1.05 to 0.88 ± 0.31 (p < .05) and a reduction in the CTS from 3.46 ± 0.57 to 1.48 ± 0.51 (p < .05). This improvement in TRSS, TMS also in CTS was significantly greater than in the rest of the group with SLIT alone or omalizumab alone. CONCLUSION: Omalizumab may be a valuable treatment that increases the effectiveness of immunotherapy in patients with severe LAR. Taylor & Francis 2022-07-11 /pmc/articles/PMC9746402/ /pubmed/35816437 http://dx.doi.org/10.1080/21645515.2022.2097818 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Immunotherapeutics – Short Report
Bozek, Andrzej
Kozłowska, Renata
Misiołek, Maciej
Ścierski, Wojciech
Gawlik, Radosław
Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
title Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
title_full Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
title_fullStr Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
title_full_unstemmed Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
title_short Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
title_sort omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis
topic Immunotherapeutics – Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746402/
https://www.ncbi.nlm.nih.gov/pubmed/35816437
http://dx.doi.org/10.1080/21645515.2022.2097818
work_keys_str_mv AT bozekandrzej omalizumabaddedtoallergenimmunotherapyincreasedtheeffectoftherapyinpatientswithseverelocalallergicrhinitis
AT kozłowskarenata omalizumabaddedtoallergenimmunotherapyincreasedtheeffectoftherapyinpatientswithseverelocalallergicrhinitis
AT misiołekmaciej omalizumabaddedtoallergenimmunotherapyincreasedtheeffectoftherapyinpatientswithseverelocalallergicrhinitis
AT scierskiwojciech omalizumabaddedtoallergenimmunotherapyincreasedtheeffectoftherapyinpatientswithseverelocalallergicrhinitis
AT gawlikradosław omalizumabaddedtoallergenimmunotherapyincreasedtheeffectoftherapyinpatientswithseverelocalallergicrhinitis